MCID: CNT033
MIFTS: 51

Central Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Cancer

MalaCards integrated aliases for Central Nervous System Cancer:

Name: Central Nervous System Cancer 12 55 15 17
Malignant Neoplasm of Central Nervous System 12
Neoplasm of the Central Nervous System 6
Neoplasm of Central Nervous System 12
Central Nervous System Neoplasms 44
Central Nervous System Neoplasm 17
Central Nervous System Tumors 12
Central Nervous System Tumor 12
Malignant Tumor of Cns 12
Cns Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3620
MeSH 44 D016543
NCIt 50 C4627 C9293
SNOMED-CT 68 93744007
ICD10 33 C72.9
UMLS 72 C0085136 C0348374

Summaries for Central Nervous System Cancer

Disease Ontology : 12 A nervous system cancer that is located in the central nervous system.

MalaCards based summary : Central Nervous System Cancer, also known as malignant neoplasm of central nervous system, is related to neurilemmomatosis and central nervous system benign neoplasm. An important gene associated with Central Nervous System Cancer is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Prednisone and Clavulanate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are Decreased sensitivity to paclitaxel and Increased proliferation

Related Diseases for Central Nervous System Cancer

Diseases in the Nervous System Cancer family:

Central Nervous System Cancer

Diseases related to Central Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 392)
# Related Disease Score Top Affiliating Genes
1 neurilemmomatosis 33.6 SMARCB1 NF2 NF1
2 central nervous system benign neoplasm 33.5 TP53 SYP GFAP
3 subependymal giant cell astrocytoma 33.5 SYP NES GFAP
4 ependymoma 33.3 SYP NF2 NES MGMT GFAP EGFR
5 spinal cancer 33.2 TP53 NF2 GFAP
6 central nervous system primitive neuroectodermal neoplasm 32.9 TP53 SYP NES GFAP
7 central nervous system germ cell tumor 32.9 NES GFAP
8 benign ependymoma 32.3 SYP NF2 GFAP
9 schwannomatosis 1 32.2 SMARCB1 NF2
10 rhabdoid cancer 31.9 TP53 SYP SMARCB1
11 rhabdoid tumor predisposition syndrome 1 31.8 TP53 SYP SMARCB1
12 atypical teratoid rhabdoid tumor 31.7 TP53 SYP SMARCB1 GFAP
13 brain cancer 31.7 TP53 SYP SMARCB1 SHH PTEN PTCH1
14 pilocytic astrocytoma 31.6 NF1 KIAA1549 IDH1 GFAP
15 meningioma, familial 31.6 TP53 SYP SMARCB1 PTEN NF2 NF1
16 malignant ependymoma 31.6 TP53 NF2 GFAP
17 mixed glioma 31.6 TP53 IDH1 GFAP
18 monosomy 22 31.5 SMARCB1 NF2
19 ganglioglioma 31.4 TP53 SYP SMARCB1 NES GFAP
20 grade iii astrocytoma 31.4 TP53 PTEN MGMT IDH2 GFAP EGFR
21 choroid plexus cancer 31.4 TP53 SMARCB1 GFAP
22 central neurocytoma 31.4 SYP NES GFAP
23 rhabdoid meningioma 31.4 SMARCB1 NF2 GFAP
24 astroblastoma 31.3 SYP NES GFAP
25 papilloma of choroid plexus 31.3 TP53 SYP GFAP
26 brain stem glioma 31.3 TP53 IDH2 IDH1 EGFR
27 anaplastic ependymoma 31.3 SYP PTEN NF2 GFAP
28 ependymoblastoma 31.3 TP53 NES GFAP
29 angiocentric glioma 31.2 SYP IDH1 GFAP
30 neuroma 31.2 SMARCB1 NF2 GFAP
31 pleomorphic xanthoastrocytoma 31.2 TP53 SYP SMARCB1 MGMT IDH1 GFAP
32 neurilemmoma 31.2 SMARCB1 NF2 NF1 NES GFAP
33 neurofibroma 31.2 SYP NF2 NF1
34 juvenile pilocytic astrocytoma 31.2 TP53 NF1 GFAP
35 pilomyxoid astrocytoma 31.2 SYP NF1 KIAA1549 GFAP
36 dysembryoplastic neuroepithelial tumor 31.1 SYP NES IDH1 GFAP
37 chordoma 31.1 SMARCB1 PTEN GFAP EGFR
38 chordoid glioma 31.1 TP53 NF2 GFAP
39 fibrillary astrocytoma 31.1 TP53 MGMT KIAA1549 IDH2 IDH1 GFAP
40 extraventricular neurocytoma 31.1 SYP IDH1 GFAP
41 desmoplastic infantile ganglioglioma 31.1 SYP GFAP
42 cellular ependymoma 31.0 TP53 SYP GFAP
43 cerebral neuroblastoma 31.0 TP53 SYP GFAP
44 malignant peripheral nerve sheath tumor 31.0 TP53 SMARCB1 NF2 NF1 EGFR
45 glioma susceptibility 1 31.0 TP53 IDH2 IDH1 GFAP
46 teratoma 31.0 TP53 SYP NES GFAP
47 medulloepithelioma 31.0 SYP NES GFAP
48 anaplastic oligodendroglioma 30.9 MGMT IDH2 GFAP EGFR
49 subependymoma 30.9 SYP NES GFAP
50 li-fraumeni syndrome 30.9 TP53 PTEN NF1 IDH1 EGFR

Graphical network of the top 20 diseases related to Central Nervous System Cancer:



Diseases related to Central Nervous System Cancer

Symptoms & Phenotypes for Central Nervous System Cancer

GenomeRNAi Phenotypes related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 NF1 PTEN
2 Increased proliferation GR00094-A 8.8 NF2 SMARCB1 TP53

MGI Mouse Phenotypes related to Central Nervous System Cancer:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.37 ARSA GFAP KIAA1549 NF1 NF2 PROM1
2 homeostasis/metabolism MP:0005376 10.37 ARSA EGFR GFAP GNRH1 IDH1 KIAA1549
3 growth/size/body region MP:0005378 10.33 EGFR GFAP GNRH1 IDH1 NF1 NF2
4 immune system MP:0005387 10.32 ARSA EGFR GFAP GNRH1 IDH1 KIAA1549
5 cardiovascular system MP:0005385 10.28 EGFR GFAP IDH2 NF1 PROM1 PTCH1
6 digestive/alimentary MP:0005381 10.23 EGFR GFAP GNRH1 NF1 PTCH1 PTEN
7 nervous system MP:0003631 10.22 ARSA EGFR GFAP GNRH1 NF1 NF2
8 endocrine/exocrine gland MP:0005379 10.21 EGFR GNRH1 MGMT NF1 NF2 PTCH1
9 neoplasm MP:0002006 10.21 EGFR GNRH1 IDH2 MGMT NF1 NF2
10 embryo MP:0005380 10.17 EGFR NF1 NF2 PTCH1 PTEN SHH
11 integument MP:0010771 10.1 EGFR GNRH1 NF1 NF2 PTCH1 PTEN
12 hearing/vestibular/ear MP:0005377 10.08 ARSA EGFR NF1 NF2 PTCH1 SHH
13 liver/biliary system MP:0005370 10.08 EGFR GNRH1 NF1 NF2 PTEN SHH
14 normal MP:0002873 10.07 EGFR GFAP GNRH1 NF1 PROM1 PTCH1
15 muscle MP:0005369 10.06 EGFR GFAP NF1 PTCH1 PTEN SHH
16 renal/urinary system MP:0005367 9.86 EGFR GNRH1 NF1 NF2 PTCH1 PTEN
17 respiratory system MP:0005388 9.81 EGFR IDH1 MGMT NF1 NF2 PTCH1
18 pigmentation MP:0001186 9.8 EGFR NF1 PROM1 PTCH1 PTEN TP53
19 skeleton MP:0005390 9.61 EGFR GNRH1 IDH1 NF1 NF2 PTCH1
20 vision/eye MP:0005391 9.32 EGFR GFAP NF1 NF2 PROM1 PTCH1

Drugs & Therapeutics for Central Nervous System Cancer

Drugs for Central Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 454)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
3
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
4 Orange Approved Phase 3
5
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Trioxsalen Approved Phase 3 3902-71-4 5585
11
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Ofloxacin Approved Phase 3 82419-36-1 4583
15
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
18
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
19
leucovorin Approved Phase 3 58-05-9 143 6006
20
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
21
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
22
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
23
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
24
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Cisatracurium Approved Phase 3 96946-41-7
27
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
28
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
29
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
30
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
32
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
33 Mitolactol Investigational Phase 3 10318-26-0
34
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
35 glucocorticoids Phase 3
36 Amoxicillin-Potassium Clavulanate Combination Phase 3
37 beta-Lactamase Inhibitors Phase 3
38 Alkylating Agents Phase 3
39 Antineoplastic Agents, Phytogenic Phase 3
40 Etoposide phosphate Phase 3
41 Antineoplastic Agents, Alkylating Phase 3
42 Gastrointestinal Agents Phase 3
43 Dihematoporphyrin Ether Phase 3
44 Hematoporphyrin Derivative Phase 3
45 Hematoporphyrins Phase 3
46 Ether Phase 3
47 Anesthetics, Inhalation Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 3
49 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
50 Antiemetics Phase 3

Interventional clinical trials:

(show top 50) (show all 603)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
2 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3 A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
4 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
5 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
6 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
9 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
10 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
11 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
12 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
13 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
14 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
15 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
16 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
17 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
18 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
19 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
20 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
21 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
22 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
23 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
24 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
25 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
26 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
27 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
28 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
29 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
30 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
31 Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
32 Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
33 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
34 A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Recruiting NCT03579602 Phase 2, Phase 3 tozuleristide
35 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
36 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
37 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
38 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
39 Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation Active, not recruiting NCT00653068 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Leucovorin Calcium;Methotrexate;Thiotepa;Vincristine Sulfate
40 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
41 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
42 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
43 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
44 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
45 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
46 Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00562419 Phase 2 CT-322;irinotecan hydrochloride
47 Phase II Trial of Pemetrexed and Temozolomide in Treating Patients With Relapsed PCNSL Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
48 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
49 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
50 A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen

Search NIH Clinical Center for Central Nervous System Cancer

Cochrane evidence based reviews: central nervous system neoplasms

Genetic Tests for Central Nervous System Cancer

Anatomical Context for Central Nervous System Cancer

MalaCards organs/tissues related to Central Nervous System Cancer:

41
Brain, Testes, Spinal Cord, T Cells, Pituitary, Bone, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Cancer:

19
Central Nervous System

Publications for Central Nervous System Cancer

Articles related to Central Nervous System Cancer:

(show top 50) (show all 158)
# Title Authors PMID Year
1
Arylsulfatase A in serum from patients with cancer of various organs. 9 38
1687888 1991
2
[Arylsulfatase A--physico-chemical properties and the use of enzyme radioimmunoassay in medical diagnosis]. 9 38
1688265 1991
3
Angiocentric glioma mimicking encephalomalacia. 38
30976372 2019
4
Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. 38
30825593 2019
5
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. 38
31049790 2019
6
Retrospective Exposure Assessment for Semiconductor and Storage Device Manufacturing Facilities. 38
30946698 2019
7
Fluorodeoxyglucose Detected Changes in Brain Metabolism After Chemotherapy in Pediatric Non-Hodgkin Lymphoma. 38
30630683 2019
8
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. 38
30350913 2019
9
Bioactive naphthoquinone and anthrone derivatives from endophytic Micromonospora sp. NEAU-gq13. 38
30585513 2018
10
Risk of Radiation-Induced Cancer From Computed Tomography Angiography Use in Imaging Surveillance for Unruptured Cerebral Aneurysms. 38
30580703 2018
11
Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients. 38
30264947 2018
12
Evidence for increased surveillance of executive functioning in adolescent and young adult survivors of childhood cancer. 38
30395335 2018
13
Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells. 38
30199037 2018
14
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. 38
29511029 2018
15
Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. 38
29427203 2018
16
Imaging Gliomas with Nanoparticle-Labeled Stem Cells. 38
29521296 2018
17
Outcomes of Organ Transplantation from Donors with a Cancer History. 38
29455213 2018
18
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. 38
29374660 2018
19
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. 38
30140655 2018
20
Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis. 38
30405856 2018
21
Gliosarcomas with the BRAF V600E mutation: a report of two cases and review of the literature. 38
28775171 2017
22
Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. 38
28426850 2017
23
Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. 38
30034079 2017
24
Improving Functional Mobility in Children and Adolescents Undergoing Treatment for Non-Central Nervous System Cancers: A Systematic Review. 38
28942910 2017
25
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. 38
28497710 2017
26
Biomarkers and Immunotherapeutic Targets in Glioblastoma. 38
28300714 2017
27
The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required. 38
28440461 2017
28
Estimating the Proportion of Childhood Cancer Cases and Costs Attributable to the Environment in California. 38
28323471 2017
29
BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation. 38
27956254 2017
30
High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform. 38
29270434 2017
31
Atypical Teratoid/Rhabdoid Tumor of the Pineal Region in a Young Adult Male Patient: Case Report and Review of the Literature. 38
27144539 2017
32
The Incidence of Malignant Tumors in Environmentally Disadvantaged Regions of Kazakhstan 38
28125862 2016
33
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. 38
27151596 2016
34
Melanotic schwannoma of the L5 root. 38
26969197 2016
35
Primary Multifocal Gliosarcoma of the Spinal Cord. 38
27134708 2016
36
Investigation of cancer mortality inequalities between rural and urban areas in South Korea. 38
26123204 2016
37
Primary atypical teratoid/rhabdoid tumor of the spine in an adult patient. 38
27069744 2016
38
Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity. 38
26806350 2016
39
Paediatric brain tumours: A review of radiotherapy, state of the art and challenges for the future regarding protontherapy and carbontherapy. 38
26548600 2015
40
Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. 38
26344551 2015
41
Cerebral gliosarcoma: Analysis of 16 patients and review of literature. 38
26396606 2015
42
Atypical teratoid rhabdoid tumour of the spine: report of a case and literature review. 38
25374299 2015
43
The isoprostanes--25 years later. 38
25449649 2015
44
Epidemiologic study of residential proximity to transmission lines and childhood cancer in California: description of design, epidemiologic methods and study population. 38
24045429 2015
45
Discovery of Potent Antiproliferative Agents Targeting EGFR Tyrosine Kinase Based on the Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine Scaffold. 38
26633023 2015
46
Effect of an Ankle Foot Orthosis Intervention for Children With Non-Central Nervous System Cancers: A Pilot Study. 38
26397091 2015
47
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. 38
25561983 2015
48
The high expressed serum soluble neural cell adhesion molecule, a high risk factor indicating hepatic encephalopathy in hepatocelular carcinoma patients. 38
25921109 2015
49
Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. 38
25058862 2014
50
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. 38
25035908 2014

Variations for Central Nervous System Cancer

ClinVar genetic disease variations for Central Nervous System Cancer:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SMARCB1 NM_003073.5(SMARCB1): c.351dup (p.Thr118fs) duplication Pathogenic rs1555876140 22:24135864-24135864 22:23793677-23793677

Expression for Central Nervous System Cancer

Search GEO for disease gene expression data for Central Nervous System Cancer.

Pathways for Central Nervous System Cancer

GO Terms for Central Nervous System Cancer

Biological processes related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.91 TP53 SHH PTEN MGMT GNRH1 EGFR
2 brain development GO:0007420 9.86 PTCH1 NF2 NF1 NES
3 negative regulation of cell migration GO:0030336 9.71 SHH PTEN NF2 NF1
4 central nervous system development GO:0007417 9.67 SHH PTEN NES ARSA
5 response to ethanol GO:0045471 9.62 PTEN MGMT GNRH1 ARSA
6 prostate gland development GO:0030850 9.61 SHH PTCH1
7 digestive tract morphogenesis GO:0048546 9.6 SHH EGFR
8 regulation of synaptic transmission, GABAergic GO:0032228 9.59 PTEN NF1
9 ectoderm development GO:0007398 9.58 SHH NF2
10 dorsal/ventral neural tube patterning GO:0021904 9.58 SHH PTCH1
11 mammary gland epithelial cell differentiation GO:0060644 9.57 PTCH1 MGMT
12 negative regulation of cell proliferation GO:0008285 9.56 TP53 SMARCB1 PTEN PTCH1 NF2 NF1
13 ovulation cycle GO:0042698 9.55 GNRH1 EGFR
14 regulation of cell proliferation GO:0042127 9.55 SHH PTCH1 NF2 NF1 EGFR
15 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 TP53 EGFR
16 NADP metabolic process GO:0006739 9.52 IDH2 IDH1
17 forebrain morphogenesis GO:0048853 9.51 PTEN NF1
18 Bergmann glial cell differentiation GO:0060020 9.49 SHH GFAP
19 regulation of protein localization to nucleus GO:1900180 9.48 SHH NF2
20 isocitrate metabolic process GO:0006102 9.46 IDH2 IDH1
21 glyoxylate cycle GO:0006097 9.26 IDH2 IDH1
22 response to organic cyclic compound GO:0014070 9.1 PTEN PTCH1 MGMT IDH1 GNRH1 EGFR

Molecular functions related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cholesterol binding GO:0015485 9.33 SYP PTCH1 PROM1
2 patched binding GO:0005113 9.26 SHH PTCH1
3 isocitrate dehydrogenase activity GO:0004448 8.96 IDH2 IDH1
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH2 IDH1

Sources for Central Nervous System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....